Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab and DFMO in Progressive High-Grade Glioma
NCT07468136Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2026
- Primary completion
- Oct 2030
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab, eflornithine in glioma, sponsored by Mayo Clinic. Started Jun 2026; status: recruiting.
02
Drugs
retifanlimabeflornithine
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07468136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07468136.